DBV Technologies S.A. (DBVT)
| Market Cap | 407.66M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -172.57M |
| Shares Out | 30.16M |
| EPS (ttm) | -3.27 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 15 |
| Last Price | $5.66 |
| Previous Close | $3.74 |
| Change ($) | 1.92 |
| Change (%) | 51.34% |
| Day's Open | 5.31 |
| Day's Range | 4.98 - 5.90 |
| Day's Volume | 17,174,176 |
| 52-Week Range | 1.38 - 12.67 |
DBV Technologies (DBVT) stock is soaring higher on Friday after providing an update on its upcoming peanut allergy treatment. The post DBVT Stock: DBV Technologies Soars on Big Peanut Allergy ...
Montrouge, France, January 14, 2020
Montrouge, France, January 7, 2021
Monthly information regarding the total number of voting rights and
Monthly information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2020
Monthly information regarding the total number of voting rights and
Montrouge, France, November 10, 2020 DBV Technologies to Highlight Data on Viaskin ™ Peanut Treatment Delivery and Patient Experience at ACAAI 2020
Montrouge, France, November 9, 2020 DBV Technologies to Participate in Upcoming Investor Conferences
The company submitted its potential peanut allergy treatment for review in Europe.
DBV Technologies S.A. (NASDAQ: DBVT) shares absolutely exploded on Monday after the firm announced that the Marketing Authorization Application (MAA) for its peanut allergy treatment was valid...
Montrouge, France, November 2, 2020
Monthly information regarding the total number of voting rights and
Monthly information regarding the total number of voting rights and
Montrouge, France, September 2, 2020
Monthly information regarding the total number of voting rights and
Shares of DBV Technologies tumbled 8.5% in premarket trading on Wednesday, the day after the company said it had received a complete response letter from the Food and Drug Administration for ...
ATLANTA--(BUSINESS WIRE)--Holzer & Holzer, LLC is investigating whether DBV Technologies S.A. (“DBV Technologies” or the “Company”) (NASDAQ: DBVT) complied with federal securities laws.
The FDA rejected the company’s application for its peanut-allergy patch.
Montrouge, France, August 4, 2020
Montrouge, France, July 20, 2020
Monthly information regarding the total number of voting rights and
Montrouge, France, July 7, 2020
Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2020
Montrouge, France, June 4, 2020
Montrouge, France, June 2, 2020
Information regarding the total number of voting rights and total number of shares of the Company as of April 30, 2020
Aimmune Therapeutics Beats DBV Technologies In Multi-Billion Dollar Market To Treat Peanut Allergies
Aimmune Therapeutics Beats DBV Technologies In Multi-Billion Dollar Market To Treat Peanut Allergies
Montrouge, France, April 20, 2020
DBV Technologies and Aimmune are at the finish line for developing novel therapies for treating peanut allergies, but each has its own twist.
DBV Technologies: Don't Panic - The Good, The Bad, And The Opportunity
Montrouge, France, April 10, 2020
Montrouge, France, March 20, 2020
Montrouge, France, March 16, 2020
Montrouge, France, March 4, 2020
Montrouge, France, March 4, 2020
Montrouge, France, March 2, 2020
Montrouge, France, February 24, 2020
Montrouge, France, February 21, 2020
Montrouge, France, February 10, 2020
Monthly information regarding the total number of voting rights and
Montrouge, France, February 6, 2020
About DBVT
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents, and adults. The company is also developing Viaskin Milk that is in Phase I/II clinical trial for the treatment of Immunoglobulin E (IgE) mediated cow's milk protein allergy (CMPA) and milk-induced eosi... [Read more...]
| Industry Biotechnology | Founded 2002 |
| CEO Daniel Tasse | Employees 311 |
| Stock Exchange NASDAQ | Ticker Symbol DBVT |
Analyst Forecasts
According to 8 analysts, the average rating for DBVT stock is "Buy." The 12-month stock price forecast is 6.76, which is an increase of 19.43% from the latest price.